Wall Street Zen Upgrades BridgeBio Oncology Therapeutics (NASDAQ:BBOT) to “Sell”

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a note issued to investors on Saturday.

Several other research analysts have also recently issued reports on BBOT. Oppenheimer started coverage on shares of BridgeBio Oncology Therapeutics in a report on Monday, June 22nd. They issued an “outperform” rating and a $22.00 target price for the company. UBS Group lowered shares of BridgeBio Oncology Therapeutics to an “overweight” rating in a research note on Wednesday, July 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research report on Thursday, June 18th. Canaccord Genuity Group began coverage on shares of BridgeBio Oncology Therapeutics in a research report on Monday, May 11th. They issued a “buy” rating and a $23.00 price target for the company. Finally, JPMorgan Chase & Co. initiated coverage on shares of BridgeBio Oncology Therapeutics in a research note on Wednesday, July 8th. They issued an “overweight” rating and a $27.00 price objective for the company. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, BridgeBio Oncology Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $24.80.

BridgeBio Oncology Therapeutics Price Performance

Shares of NASDAQ BBOT opened at $8.56 on Friday. The stock’s 50-day simple moving average is $8.16. The firm has a market cap of $685.74 million, a price-to-earnings ratio of -4.18 and a beta of 0.39. BridgeBio Oncology Therapeutics has a fifty-two week low of $7.00 and a fifty-two week high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($526.11) earnings per share (EPS) for the quarter. On average, sell-side analysts forecast that BridgeBio Oncology Therapeutics will post -2.3 earnings per share for the current year.

Hedge Funds Weigh In On BridgeBio Oncology Therapeutics

Hedge funds have recently modified their holdings of the business. Catalio Capital Management LP purchased a new stake in BridgeBio Oncology Therapeutics in the 4th quarter valued at $5,142,000. Armistice Capital LLC boosted its stake in BridgeBio Oncology Therapeutics by 142.7% during the 4th quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock worth $12,520,000 after purchasing an additional 588,000 shares during the period. BIT Capital GmbH purchased a new position in BridgeBio Oncology Therapeutics during the 4th quarter worth $313,000. XTX Topco Ltd grew its position in BridgeBio Oncology Therapeutics by 22.4% during the 4th quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock worth $358,000 after purchasing an additional 5,249 shares during the last quarter. Finally, Quadrature Capital Ltd acquired a new position in BridgeBio Oncology Therapeutics in the fourth quarter valued at $162,000. 54.89% of the stock is currently owned by hedge funds and other institutional investors.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.